zurück
Melphalan flufenamide (multiple myeloma, ≥ 3 prior therapies, in combination with dexamethasone)
Subject:
- Active Substance: Melphalan flufenamide
- Name: Pepaxti®
- Therapeutic area: Multiple myeloma
- Pharmaceutical company: Oncopeptides AB
Time table:
- Start: 01.10.2022
- Final decision by G-BA: 16.03.2023
Final decision:
- No additional benefit proved